Lipids in Atherosclerosis

The role of oxidized lipids in cardiovascular diseases (CVD) has been investigated over the last three decades extensively. A number of studies have been carried out on the mechanisms, and pathways leading to the arterial atherosclerosis.

Atherosclerosis is the leading cause of death in North America and within the next two decades will be the leading cause worldwide. Atherosclerosis is characterized by vascular obstruction from the deposits of plaque, resulting in reduced blood flow. Plaque rupture and the consequent thrombosis may lead to sudden blockage of the arteries and cause heart attack. High serum lipid levels, especially the elevated level of low-density lipoproteins (LDL), have been shown to be strongly related to the development of atherosclerosis. It is generally accepted that atherosclerotic lesions are initiated via an enhancement of LDL uptake by monocytes and macrophages. In the liver, uptake of plasma LDL is mediated via specific LDL receptors, but a scavenger receptor system is employed by macrophages. Plasma LDL must be modified prior to uptake by macrophages.

 

  • Cerebrovascular disease
  • Transient ischemic attacks (TIAs)
  • Angioplasty
  • Coronary heart disease (CHD)
  • Carotid artery disease
  • Arteriosclerosis
  • Hardening of the arteries
  • Coronary microvascular disease (MVD)
  • Echocardiography
  • Computed tomography scan
  • Familial hypercholesterolaemia (FH)
  • Elevated levels of LDL cholesterol and apolipoprotein B (apoB)
  • Ischemia
  • Ischemia

Related Conference of Lipids in Atherosclerosis

May 04-05, 2026

7th International Conference on Drug Chemistry

Paris, France
September 03-04, 2026

16th World Glycobiology Congress

Aix-en-Provence, France
September 21-22, 2026

24th International Conference on Structural Biology

A Coruna, Spain

Lipids in Atherosclerosis Conference Speakers